Nuclear factor kappa B inhibition promotes closure of the rat ductus arteriosus (866.8)

Intravenous Paracetamol and Patent Ductus Arteriosus Closure

Background: Standard medical treatments for patent ductus arteriosus (PDA) closure are, including indomethacin/ibuprofen and surgical ligation. Nowadays, a new strategy to close PDA is the use of paracetamol. The present study aimed to describe the use of intravenous (IV) paracetamol for PDA closure in neonates who present a contraindication to ibuprofen or ibuprofen failure with no possibility...

Closure of Small Patent Ductus Arteriosus by Occluding Detachable Coil

Thromboxane A2 Receptor Stimulation Promotes Closure of the Rat Ductus Arteriosus through Enhancing Neointima Formation

Ductus arteriosus (DA) closure follows constriction and remodeling of the entire vessel wall. Patent ductus arteriosus occurs when the DA does not close after birth, and this condition is currently treated using cyclooxygenase inhibitors. However, the efficacy of cyclooxygenase inhibitors is often limited. Our previous study demonstrated that low-dose thromboxane A2 receptor (TP) stimulation co...

The Physiologic Closure of the Ductus Arteriosus

The exact time of functional closure of the ductus arteriosus in the newborn human infant has remained a matter of speculation for many years. Studies of human anatomical specimens have shown that complete morphologic closure requires from four to eight weeks (1-5). Animal experiments have been the main approach to the study of functional closure. All workers agree that at the time of birth, bu...

Transcatheter closure of the patent ductus arteriosus.

Patent ductus arteriosus (PDA) is one of the most common congenital heart defects. Although surgery is still required in symptomatic neonates, the majority of older infants and children can undergo safe and effective transcatheter device closure on an out-patient basis. First described in 1967, over the past four decades, numerous devices have been specifically developed for this purpose. This ...